The following summarizes publicly available year over year earnings results to date. Our estimates place year over year market growth at 5% thus far, as indicated in Exhibit 1, which displays growth by product segment. Performance highlights relate to 2010, unless otherwise noted.
Exhibit 1: Orthopaedic Sales1 Increases by Product Segment: 2010 vs. 2009
1Orthopaedic products only; constant currency, pro forma growth
2For the quarter ended 11/30/10; excludes dental; trauma includes stimulators; spine includes stimulators and orthobiologics.
Biomet (for fiscal 2Q11, ended 11/30/10)
- U.S. $416.9MM, +2%
- Europe $188.8MM, -1%
- International $92.6MM, +7%
Reconstructive $540.5MM, +3% (U.S. +3%)
- Hips flat (U.S. flat)
- Knees +3% (U.S. +3%)
- Extremities +23% (U.S. +36%)
- Other -3% (U.S. -2%)
Fixation $56.3MM, -2% (U.S. -1%)
Spine $56.0MM, -3% (U.S. flat)
Other $45.5MM, +2% (U.S. +2%)
- Sports Medicine +17% (U.S. +17%)
- Other -14% (U.S. -16%)
Overall growth includes Dental.
- Not observing a lot of movement in larger U.S. hospital customers toward purchasing to eliminate the distributor and manage inventory on their own